Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | USP19 | O94966 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978058 | 0.89 | KMT2A (0.35) | KMT2AF10SCN9AUSP19MEN1 | |
| Hydrochloric Acid SCHEMBL3999990 | 0.87 | KMT2A (0.34) | KMT2ASCN9AUSP19MEN1 | |
| SCHEMBL5337457 | 0.84 | JAK2 (0.34) | F10USP19 | |
| SCHEMBL1583265 | 0.81 | MEN1 (0.49) | KMT2AALDH1A1L3MBTL1TSHRHSD17B10 | |
| SCHEMBL22123100 | 0.81 | CXCR4 (0.33) | KMT2AF10MEN1 | |
| SCHEMBL8486724 | 0.80 | — | — | |
| Bromide SCHEMBL28431073 | 0.80 | MEN1 (0.47) | KMT2AALDH1A1L3MBTL1TSHRHSD17B10 | |
| SCHEMBL19980682 | 0.80 | CXCR4 (0.35) | F10 | |
| SCHEMBL27789194 | 0.80 | F10 (0.31) | F10 | |
| SCHEMBL161338 | 0.80 | MEN1 (0.43) | KMT2AALDH1A1TSHRHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115646137-B | Organic amine desulfurizing agent capable of effectively reducing foaming problem | 北京北大先锋科技股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-115646137-A | Organic amine desulfurizer capable of effectively reducing foaming problem | 北京北大先锋科技股份有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-115646137-B | Organic amine desulfurizing agent capable of effectively reducing foaming problem | 北京北大先锋科技股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-115646137-A | Organic amine desulfurizer capable of effectively reducing foaming problem | 北京北大先锋科技股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-112973419-A | Proportion-controllable composite hydroxyalkyl piperazine desulfurizer as well as preparation method and application thereof | 合肥工业大学 | 2021-06-18 | — | — | CN | disclosed |
| EP-1528925-B1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-7504408-B2 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2005-11-10 | — | — | US | disclosed |
| EP-1528925-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004004732-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | TPD52L2, NQO2, CCNI | KMT2A 706/4885ALDH1A1 1137/4885PABPC1 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.